Skip to main content
Clinical Trials/NL-OMON40554
NL-OMON40554
Completed
Not Applicable

Advanced PET and MRI techniques for improved therapy response assessment in diffuse large B-cell lymphoma / follicular lymphoma grade 3B - MITRAL; molecular imaging techniques for response assessment in lymphoma

niversitair Medisch Centrum Utrecht0 sites110 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diffuse large B-cell lymphoma / follicular lymphoma grade 3B
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
110
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • \- Male or female patients
  • \- Age: 18 years and older
  • \- Histologically proven diffuse large B\-cell lymphoma / Follicular lymphoma grade 3B
  • \- Patients scheduled to undergo front\-line R\-CHOP 21 therapy
  • \- Patients must be capable of giving written informed consent and the consent must have been obtained before the study\-related procedures

Exclusion Criteria

  • \- General contraindications for MRI (including cardiac pacemakers and claustrophobia). \- Previous malignancy. However, subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non\-melanoma skin cancer, or successfully treated in situ carcinoma are eligible. \- Diffuse large B\-cell lymphoma / follicular lymphoma grade 3B central nervous system involvement. \- Diffuse large B\-cell lymphoma / follicular lymphoma grade 3B stage I disease. \- HIV positivity (de novo or active) \- Pregnant or lactating women. \- Therapy has already started before pretreatment dual\-time point 18F\-FDG PET and DWI scans could be performed.

Outcomes

Primary Outcomes

Not specified

Similar Trials